Treatment of Psychiatric Disorders

Medication Efficacy and Safety

• Cariprazine is effective for negative symptoms, with a moderate strength of evidence, as recommended by the American College of Psychiatry 1
• Quetiapine may provide better sedation for sleep disturbances, with a low to moderate strength of evidence, as recommended by the American Academy of Sleep Medicine 2, 3
• SSRIs, such as sertraline, are first-line pharmacological treatments for agitation, particularly in vascular cognitive impairment, with a typical dosage of 25-100 mg daily, as recommended by the American Geriatrics Society 4, 5
• Mirtazapine offers additional benefits, including appetite stimulation and sleep improvement, although it may cause more sedation than desired, with a starting dose of 7.5-15 mg at bedtime 5
• Quetiapine, risperidone, and aripiprazole are second- and third-line options for agitation in elderly patients, with initial dosages of 12.5-25 mg orally twice daily, 0.25-0.5 mg orally at bedtime, and 5 mg orally daily, respectively 6, 7

Cardiovascular Risks

• The combination of certain medications can potentially prolong QTc interval, requiring ECG monitoring, especially in patients with pre-existing cardiac conditions, as suggested by the American Academy of Pediatrics, with a moderate strength of evidence 8
• All antipsychotics can prolong QTc interval, and monitoring of ECG is recommended in high-risk patients, particularly with haloperidol alone, and extrapyramidal symptoms (EPS) should be monitored, particularly with haloperidol alone 9
• Antipsychotics carry an FDA black box warning regarding increased mortality risk in dementia patients and should be avoided or used only as a last resort at the lowest effective dose for the shortest duration possible, as recommended by the American College of Psychiatry 10, 11, 12
• The European Heart Journal recommends avoiding combination therapy with more than one QTc-prolonging agent, and if QTc increases by >60 ms or exceeds 500 ms, the QTc-prolonging medication should be discontinued 13

Non-Pharmacological Interventions

• Non-pharmacological approaches, such as simulated presence therapy, massage therapy, animal-assisted interventions, and personally tailored interventions, should be tried first to manage agitation, as recommended by the American Geriatrics Society 4
• Environmental modifications, such as creating calming physical environments with decreased sensory stimulation, can help reduce agitation, as recommended by the American Academy of Pediatrics 8
• De-escalation techniques, including verbal restraint strategies and crisis intervention training for caregivers, can be effective in managing aggression, according to the American Academy of Pediatrics 8

Assessment and Monitoring

• It is essential to assess for underlying causes of aggression, including physical discomfort or pain, environmental triggers, psychiatric conditions, and communication difficulties, before initiating treatment, as suggested by the American Academy of Pediatrics 8
• Use validated anxiety assessment tools, such as the Penn State Worry Questionnaire-Abbreviated (PSWQ-A) with a cut-off of 17 and the Geriatric Anxiety Inventory (GAI) with a cut-off score of 8 for mild/moderate dementia 14
• Schedule follow-up within 2 weeks to assess response to medication changes, monitoring agitation/anxiety levels, fall frequency, cognitive function, withdrawal symptoms, and vital signs 10
• Regular reassessment every 2-4 weeks initially to monitor medication side effects, cognitive function, falls risk, QT prolongation, and therapeutic response 4, 10, 15

Dosing Schedule

6

Emergency Management

• The European Journal of Heart Failure suggests administering IV magnesium sulfate (10 mL) if torsades de pointes develops, and considering temporary transvenous pacing or isoproterenol for persistent cases, and recommends immediate defibrillation for sustained ventricular arrhythmias with hemodynamic instability 16